Royalty Pharma Plc (RPRX) financial statements
Royalty Pharma Plc reported revenue of $2.4B in fiscal 2025, up 4.1% a year over 7 years.
Net income was $771M and the operating margin 65.6%, against 76.0% in 2018.
The diluted share count rose 50% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Royalty Pharma Plc's 10-K filings with the SEC.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.8B | $1.8B | $2.1B | $2.3B | $2.2B | $2.4B | $2.3B | $2.4B |
| Research and development | $393M | $83M | $26M | $200M | $177M | $52M | $2M | $452M |
| Selling, general and admin | $62M | $103M | $182M | $183M | $227M | $250M | $237M | $573M |
| Operating income | $1.4B | $2.6B | $1.6B | $1.4B | $307M | $1.5B | $1.3B | $1.6B |
| Interest expense | $280M | $269M | $157M | $166M | $188M | $187M | $226M | $308M |
| Pre-tax income | $1.5B | $2.5B | $1.7B | $1.2B | $230M | $1.7B | $1.3B | $1.3B |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | $1.4B | $2.3B | $975M | $620M | $43M | $1.1B | $859M | $771M |
| EPS (diluted) | — | — | $1.32 | $1.49 | $0.10 | $2.53 | $1.91 | $1.78 |
| Diluted shares | — | — | 375M | 415M | 438M | 603M | 594M | 564M |
| Operating margin | 76.0% | 144.6% | 75.2% | 62.5% | 13.7% | 63.4% | 57.1% | 65.6% |
| Net margin | 76.8% | 129.4% | 45.9% | 27.1% | 1.9% | 48.2% | 37.9% | 32.4% |
Balance sheet
Fiscal years, from Royalty Pharma Plc's 10-K filings with the SEC.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $1.9B | $246M | $1.1B | $1.6B | $1.7B | $495M | $987M | $637M |
| Total current assets | — | $832M | $2.7B | $2.9B | $2.6B | $1.3B | $1.8B | $1.5B |
| Goodwill | — | — | — | — | — | — | $0 | $925M |
| Total assets | — | $12.4B | $16.0B | $17.5B | $16.8B | $16.4B | $18.2B | $19.6B |
| Total current liabilities | — | $333M | $308M | $171M | $1.2B | $161M | $1.3B | $636M |
| Long-term debt | — | $6.0B | $5.8B | $7.1B | $6.1B | $6.1B | $6.6B | $8.6B |
| Total liabilities | — | $6.3B | $6.1B | $7.3B | $7.3B | $6.3B | $7.9B | $9.9B |
| Shareholders' equity | $4.6B | $6.1B | $9.9B | $10.2B | $9.5B | $10.1B | $10.3B | $9.7B |
| Net debt | -$1.9B | $6.0B | $4.8B | $5.6B | $5.4B | $5.7B | $6.7B | $8.3B |
Cash flow
Fiscal years, from Royalty Pharma Plc's 10-K filings with the SEC.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.6B | $1.7B | $2.0B | $2.0B | $2.1B | $3.0B | $2.8B | $2.5B |
| Stock-based compensation | $0 | $0 | $5M | $2M | $2M | $2M | $2M | $290M |
| Share buybacks (net) | $0 | -$4M | $0 | $0 | $0 | -$305M | -$230M | -$1.2B |
| Net borrowing | $0 | $0 | $775M | $1.3B | $0 | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for RPRX.
Open RPRX in InvestinglyQuestions
What was Royalty Pharma Plc's revenue in 2025?
$2.4B in fiscal 2025, from its 10-K filing.
From Royalty Pharma Plc's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.